-
In-hospital management of patients with thrombocytopenia caused by blood system diseases (2) - aplastic anemia
Time of Update: 2022-01-27
The standard therapy for severe AA is immunosuppressive therapy (IST) with ATG/ALG and cyclosporin A (CsA) for patients aged >35 years or aged ≤35 years without HLA-identical sibling donors; For severe AA patients aged ≤35 years with HLA-identical sibling donors, if there is no active infection and bleeding, HLA-identical sibling donors are the first choice for hematopoietic stem cell transplantation .
-
ASH's new "shi" Li Song Yuqin and Zhang Huilai: Double-antibody Glofitamab helps T-cell immunotherapy start a new journey, and the unique administration method effectively improves the safety profile
Time of Update: 2022-01-27
Immunotherapy-induced CRS5 The current key clinical research safety data of CAR-T cell therapy compares Glofit's unique drug regimen to help reduce the incidence of CRS In the field of non-Hodgkin's lymphoma (NHL) treatment, in addition to CAR-T cell therapy, Another important research direction in tumor therapy mediated by T cells is bispecific antibodies, which can target two different antigen-binding sites: one for tumor antigens and the other for activating cytotoxic cells to exert anti-tumor activity .
-
Case Sharing Prof. Song Yuqin: Breaking the Dilemma of Drug Resistance in Conventional Chemotherapy, DLBCL Patients Treated with Selinesol Obtained Sustained Effective Remission
Time of Update: 2022-01-27
Professor Song Yuqin Deputy Director, Chief Physician and Doctoral Supervisor of the Lymphoma Department of Peking University Cancer Hospital Director of the Chinese Society of Clinical Oncology (CSC
-
In-hospital management of patients with thrombocytopenia caused by hematological diseases (3) - hematopoietic stem cell transplantation
Time of Update: 2022-01-27
Bleeding severity graded thrombocytopenia after hematopoietic stem cell transplantation and bleeding-related complications are one of the main causes of death in patients undergoing HSCT .
-
Annual Inventory Summary of 2021 Updates to Popular Guidelines in the Field of Blood Disorders
Time of Update: 2022-01-26
Peng Jun: Adults Updated Interpretation of Chinese Guidelines for Diagnosis and Treatment of ITP (2020 Edition)China Hematology Development Conference 3.
Interview with Professor Yang Renchi | "China Hemophilia Management Guidelines (2021 Edition)" was released to help develop a new pattern of hemophilia diagnosis and treatment in China3 .
-
NEJM continuously reports that Eltrombopag has a long way to go in the treatment of aplastic anemia, and we are searching for it
Time of Update: 2022-01-26
On January 6, 2022, the New England Journal of Medicine (NEJM) published the results of the RACE trial in Europe, confirming that the standard immunotherapy regimen combined with eltrombopag in severe and very severe aplastic anemia improved the rate of hematologic response, speed and intensity .
-
Acalatinib, veneclax, and octuzumab have excellent efficacy in newly diagnosed CLL
Time of Update: 2022-01-26
Fixed-duration therapy with the BCL-2 inhibitor veneclax combined with the anti-CD20 antibody octuzumab is also effective, but high-risk cytogenetics such as TP53 abnormalities (ie, TP53 mutation or 17p deletion, or both) or IGHV- Patients with unmutated CLL may not experience durable benefit .
-
Dose-finding study of ponatinib in chronic phase chronic myeloid leukemia patients
Time of Update: 2022-01-26
Patients in the 45 mg and 30 mg groups required a dose reduction to 15 mg once daily when BCR-ABL1IS reached ≤1% .
Figure 1: The once-daily ponatinib response study also calculated the cumulative rate of BCR-ABL1IS ≤1% at 12 months in each subgroup of patients .
-
Express reduced the bleeding rate by 85%, and the long-term effect of the phase 3 clinical trial of hemophilia gene therapy was positive
Time of Update: 2022-01-26
Results of the trial showed that patients who received a single gene therapy treatment had an 85% reduction in annual bleeding rate (ABR) from baseline after two years of treatment, which was superior to coagulation factor VIII prophylaxis .
-
Efficacy and safety evaluation of a novel ROCK2 inhibitor belumosudil in chronic graft-versus-host disease: the ROCKstar study
Time of Update: 2022-01-26
We conducted a phase II randomized multicenter registry study (ROCKstar; KD025-213) evaluating belumosudil 200 mg once daily (n = 66) and 200 mg twice daily (n = 66) in patients with prior 2- Efficacy and safety of 5 treatments in patients with cGVHD .
-
2021ASH Professor Chen Wenming: The primary endpoint of the GMMG-HD7 phase III trial has been reached, and the MRD-negative rate of Isa-RVd in the treatment of NDMM patients exceeds 50%
Time of Update: 2022-01-26
The first primary endpoint of the label, multicenter Phase III clinical trial was minimal residual disease (MRD) negativity after induction therapy with RVd and Isa-RVd in transplant-eligible NDMM patients .
-
Annual Review Prof. Zhiming Li: Review and Prospect of Hodgkin Lymphoma Research Progress in 2021
Time of Update: 2022-01-26
The ECHELON-1 study, presented at the 2021 EHA meeting, explored BV + AVD (doxorubicin + vinblastine + dacarbazine) combined with chemotherapy in the treatment of untreated stage III/IV classical Hodgkin lymphoma (cHL) The 5-year follow-up results showed that the BV+AVD group had a more significant benefit in progression-free survival (PFS) than the ABVD group (5-year PFS rate: 82.
-
Annual review of new drugs and programs approved by the FDA for hematological malignancies in 2021
Time of Update: 2022-01-26
July 16, 2021 FDA approves selective Rho-related coiled-coil kinase 2 (ROCK2) inhibitor belumosudil for the treatment of chronic graft-versus-host disease (cGVHD) in adults and children ≥12 years of age who have failed ≥2 previous lines of systemic therapy The approval was based on a randomized, open-label, multicenter study (KD025-213 study) .
-
In-hospital management of patients with thrombocytopenia due to hematological diseases (5) - Thrombocytopenia due to chemotherapy in acute leukemia
Time of Update: 2022-01-26
Therefore, improving platelet levels and reducing bleeding risk in leukemia patients after chemotherapy is the first choice for clinical treatment of CIT .
-
[Research] A new technology can greatly reduce the risk of leukemia complications!
Time of Update: 2022-01-26
The study reports that only 7% of leukemia patients who received stem cell transplants without naive T cells developed chronic graft-versus-host disease (GVHD), compared with 30% to 60% of standard care.
-
In-hospital management of patients with thrombocytopenia caused by hematological diseases (4) - myelodysplastic syndrome
Time of Update: 2022-01-26
In MDS patients with del(5q), lenalidomide is not recommended if the following conditions occur: ① the proportion of bone marrow blasts > 5%; ② complex karyotype; ③ IPSS-intermediate-risk-2 or high-risk group; ④ TP53 gene mutation .
-
Big coffee explores "Ao", clears the clouds and sees the moon, and precise targeted therapy leads the future treatment direction of FL
Time of Update: 2022-01-26
Based on this, Yimaitong specially invited Professor Liu Lin and Professor Tang Xiaoqiong from the First Affiliated Hospital of Chongqing Medical University to discuss the precise targeted therapy of FL, and explore the application of otuzumab in the field of FL under the fine stratification strategy .
-
First hemophilia gene therapy coming to market?
Time of Update: 2022-01-26
January 11, 2022 / eMedClub News/--Recently, BioMarin announced the complete data of the hemophilia gene therapy valoctocogene roxaparvovec (hereinafter referred to as: valrox) in the Phase 3 clinical study GENEr8-1.
-
Learning from both China and the West, focusing on the gathering of big names in the "shi" world, focusing on the frontier progress of hematology and tumor, and promoting in-depth exchanges in the field
Time of Update: 2022-01-26
In a phase Ib study of the safety of a novel T cell-binding bispecific antibody Glofitamab (hereinafter referred to as Glofit) combined with R-CHOP regimen for newly treated DLBCL, preliminary data showed that the overall response rate of 9 patients was as high as 100% , In terms of safety, the incidence of CRS in patients is extremely low, and there is no ICANS adverse event, and more samples are expected to be verified in the future .
-
Annual inventory of 2021 acute lymphoblastic leukemia research progress summary
Time of Update: 2022-01-25
When medical insurance is in progress | Care for ALL: Belintoumumab helps patients with relapsed or refractory acute lymphoblastic leukemia to open the era of immunotherapy 03 Antibody-drug conjugates (ADC) 1.